GlassScriptPhysician profile
Ramsha A Kudia
NPI 1811359151
$2,451.97
in general payments reported to CMS, 2019-2025
20 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.11 · 2020: $70.12 · 2023: $108 · 2024: $1,074 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.51 |
| Education | $194.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $387.79 | 2023-2025 | Tremfya |
| Abbvie INC. | $336.38 | 2023-2025 | |
| Ucb, INC. | $333.41 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $309.10 | 2020-2025 | Krystexxa, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $208.48 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $194.25 | 2023-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $145.08 | 2024-2025 | |
| Pfizer INC. | $129.14 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $102.01 | 2024-2025 | Acthar |
| Lilly USA, LLC | $68.23 | 2024-2025 | Zepbound, Taltz |
| Actelion Pharmaceuticals US, INC. | $45.06 | 2024 | Opsumit, Uptravi |
| Radius Health, INC. | $34.77 | 2025 | |
| Allergan, INC. | $28.27 | 2020 | |
| Boston Scientific Corporation | $24.47 | 2023 | |
| Genentech USA, INC. | $23.57 | 2024 | Actemra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $19.50 | 2024 | |
| Sobi, INC | $19.25 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.11 | 2019 | |
| Saluda Medical Americas, INC. | $13.86 | 2025 | Evoke |
| Merck Sharp & Dohme LLC | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsha Kudia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.